Media » Invitation to submit interest in a sublicence for sutezolid

Invitation to submit interest in a sublicence for sutezolid

Investigational Tuberculosis Candidate Sutezolid

The Medicines Patent Pool (MPP) is currently inviting interested product developers to indicate an interest in a sublicence for investigational tuberculosis treatment sutezolid. Patent holder Johns Hopkins University granted the MPP an exclusive, royalty-free licence covering all countries that currently have patents issued or pending for a combination therapy comprising sutezolid and two additional compounds used to treat TB such as pretomanid, delamanid, bedaquiline, rifampicin and moxifloxacin.

The agreement allows sub-licensees to develop, make, have made, use, file for regulatory approval, sell, import and export sutezolid worldwide. The full text of the agreement can be found here.

Per the licence’s terms and conditions, the foundation seeks to grant sub-licences to any entity that can demonstrate a willingness and capacity to further develop and commercialise the product and make the product widely available. The MPP will also require any sub-licensee to agree upon reasonable diligence requirements and development milestones.

Interested parties should also submit as much detail as possible to help MPP understand whether, and to what extent, a granted sub-licence will help improve sustainable access to improved regimens to treat tuberculosis. Applications should include an assessment of an organisation’s state of readiness, experience in tuberculosis research and development, and access to resources for further development.

Please contact the foundation’s General Counsel Chan Park for further clarifications about proposal format and content.

About the Medicines Patent Pool

The MPP is an independent public health foundation based in Geneva, Switzerland, established with the support of UNITAID. The mission of the MPP is to increase access to medicines and technologies for HIV, tuberculosis and hepatitis C, and facilitate development of better-adapted medicines and technologies, such as fixed-dose combinations and special formulations for children, by creating a pool of relevant patents for sub-licensing and product development.

For more information, please see our website,

This website uses cookies to ensure you get the best experience on our website. Learn More